Blood test could replace painful biopsies for cancer patients
NCT ID NCT05057234
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a blood test (liquid biopsy) can find cancer mutations as well as the standard tissue biopsy. Researchers will compare the two methods in 1,500 advanced cancer patients to see if the blood test helps doctors choose better treatments and saves money. The goal is to make precision medicine easier and less invasive for patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- FoundationOne liquid CDx (a blood test that looks for cancer DNA)
- What this could lead to
- If successful, this could show that a simple blood test can replace or supplement tissue biopsies, making precision cancer treatment faster and more accessible.
- What could go wrong
- This is an observational study, not a treatment trial. It compares two testing methods, so it won't directly improve outcomes. The blood test may miss some mutations found in tissue, and results may not apply to all cancer types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
BC Cancer
Vancouver, British Columbia, V5Z4E6, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Could sitting up make radiation therapy more comfortable?
- Can we predict dangerous side effects when combining radiation and immunotherapy?
- Family history as a shield: can culturally tailored guidance cut cancer risk?
- A simple screening program could transform cancer aftercare